Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment

Simple item page
dc.contributor.buuauthorUsta, Mehmet
dc.contributor.buuauthorErsoy, Alparslan
dc.contributor.buuauthorDilek, Kamil
dc.contributor.buuauthorÖzdemir, Bülent
dc.contributor.buuauthorYavuz, Mahmut
dc.contributor.buuauthorGüllülü, Mustafa
dc.contributor.buuauthorYurtkuran, Mustafa Abbas
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nefroloji Bilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-0710-0923tr_TR
dc.contributor.researcheridAAH-5054-2021tr_TR
dc.contributor.scopusid7005030712tr_TR
dc.contributor.scopusid35612977100tr_TR
dc.contributor.scopusid56005080200tr_TR
dc.contributor.scopusid7004168959tr_TR
dc.contributor.scopusid7006244754tr_TR
dc.contributor.scopusid6602684544tr_TR
dc.contributor.scopusid7003389525tr_TR
dc.date.accessioned2022-03-22T13:05:26Z
dc.date.available2022-03-22T13:05:26Z
dc.date.issued2003-03
dc.description.abstractObjectives. Angiotensin II may play an important role in the progression of renal disease. Currently, angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists are commonly used for renoprotection. To our knowledge, there is no study investigating this effect of angiotensin II receptor antagonists in patients with primary focal segmental glomerulosclerosis (FSGS) in the literature. The aim of this study was to evaluate the effects of losartan on proteinuria and renal function in patients with FSGS refractory to immunosuppressive treatment. Design. Twenty-three normotensive patients with FSGS proven through renal biopsy were included in the study. Thirteen of them, five men and eight women, were given losartan in a dose of 50 mg day(-1) during 12 months, and 10, four men and six women, were in the control group. Mean arterial blood pressure (MAP), 24-h urine protein excretion, serum total protein and albumin levels were determined just before the start of treatment as well as after 1, 6 and 12 months of the study. In addition, serum creatinine, creatinine clearence (CrCl), cholesterol and triglyceride levels were determined at the beginning and end of the study. Results. Age, gender and baseline levels of proteinuria, serum albumin, total protein, creatinine, CrCl and MAPs were similar in the two groups. Nephrotic range of proteinuria was present in five of 13 patients (38.4%) in the losartan group and in four of 10 patients (40%) in the control group. In the losartan group, 24-h proteinuria had decreased from 3.6 +/- 0.5 g to 2.3 +/- 0.5 g after 1 month, to 2.4 +/- 0.7 g after 6 months and to 1.9 +/- 0.7 g after 12 months. In the control group, a significant increase in proteinuria compared with the baseline value was noticed after 12 months. Proteinuria levels were significantly higher in the control group than in the losartan group after 6 and 12 months. Whilst total protein and albumin levels increased in the losartan group, they did not change significantly in the control group. The total protein levels after 6 and 12 months, and albumin levels after 6 months were significantly higher in the losartan group than in the control group. No significant change was observed between the baseline and the 12-month creatinine and CrCl levels of the groups when intra- and inter-group comparisons were made. Furthermore, serum cholesterol levels of the losartan group were reduced significantly. The changes in MAP values did not reach significant levels in either of the groups. There was no correlation between the percentage changes in MAP and in proteinuria of the losartan group after 12 months. Conclusions. Angiotensin II receptor antagonists may be an alternative therapy in FSGS patients who are resistant to immunosuppressive therapy.en_US
dc.identifier.citationUsta, M. vd. (2003). “Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment”. Journal of Internal Medicine, 253(3), 329-334.en_US
dc.identifier.endpage334tr_TR
dc.identifier.issn0954-6820
dc.identifier.issue3tr_TR
dc.identifier.pubmed12603500tr_TR
dc.identifier.scopus2-s2.0-0037335776tr_TR
dc.identifier.startpage329tr_TR
dc.identifier.urihttps://doi.org/10.1046/j.1365-2796.2003.01071.x
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2796.2003.01071.x
dc.identifier.urihttp://hdl.handle.net/11452/25279
dc.identifier.volume253tr_TR
dc.identifier.wos000181230700009tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.journalJournal of Internal Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGeneral and internal medicineen_US
dc.subjectAngiotensin receptor blockadeen_US
dc.subjectFocal segmental glomerulosclerosisen_US
dc.subjectLosartanen_US
dc.subjectProteinuriaen_US
dc.subjectTreatment resistanten_US
dc.subjectConverting-enzyme-inhibitionen_US
dc.subjectRenin-angiotensin systemen_US
dc.subjectRenal-functionen_US
dc.subjectGlomerular sclerosisen_US
dc.subjectNephropathyen_US
dc.subjectProteinuriaen_US
dc.subjectAblationen_US
dc.subjectRamiprilen_US
dc.subjectDeclineen_US
dc.subjectTherapyen_US
dc.subject.emtreeAngiotensin 2 receptor antagonisten_US
dc.subject.emtreeCreatinineen_US
dc.subject.emtreeDipeptidyl carboxypeptidase inhibitoren_US
dc.subject.emtreeLosartanen_US
dc.subject.emtreePlasma proteinen_US
dc.subject.emtreeAntihypertensive agenten_US
dc.subject.emtreeAzathioprineen_US
dc.subject.emtreeCorticosteroiden_US
dc.subject.emtreeCyclophosphamideen_US
dc.subject.emtreeImmunosuppressive agenten_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeen_US
dc.subject.emtreeAlbumin blood levelen_US
dc.subject.emtreeArterial pressureen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeControlled clinical trialen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeCreatinine clearanceen_US
dc.subject.emtreeDrug resistanceen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGenderen_US
dc.subject.emtreeGlomerulosclerosisen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeImmunosuppressive treatmenten_US
dc.subject.emtreeMaleen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeProteinuriaen_US
dc.subject.emtreeBlood pressureen_US
dc.subject.emtreeDrug combinationen_US
dc.subject.emtreeDrug effecten_US
dc.subject.emtreeFocal glomerulosclerosisen_US
dc.subject.emtreeProteinuriaen_US
dc.subject.emtreeRandomized controlled trialen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeUrineen_US
dc.subject.meshAdrenal cortex hormonesen_US
dc.subject.meshAdulten_US
dc.subject.meshAntihypertensive agentsen_US
dc.subject.meshAzathioprineen_US
dc.subject.meshBlood pressureen_US
dc.subject.meshCyclophosphamideen_US
dc.subject.meshDrug resistanceen_US
dc.subject.meshDrug therapy, combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshGlomerulosclerosis, focal segmentalen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunosuppressive agentsen_US
dc.subject.meshLosartanen_US
dc.subject.meshMaleen_US
dc.subject.meshProteinuriaen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.scopusRenin Angiotensin Aldosterone System; Angiotensin Receptor Antagonists; Chronic Kidney Failureen_US
dc.subject.wosMedicine, general and internalen_US
dc.titleEfficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatmenten_US
dc.typeArticle
dc.wos.quartileQ1en_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Usta_vd_2003.pdf
Size:
70.13 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus